Traci Goldstein
Corneal and Contact Management · New York, NYNPI 1609961192
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 144 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 19 manufacturers, the largest accounting for just 18.7% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $916, 2.2 times the $426 reported in 2019.
Across 144 payments — averaging $24.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bausch & Lomb Americas Inc.$669
- AbbVie$579
- Sun Pharmaceutical Industries Inc.$562
- Alcon$254
- Tarsus Pharmaceuticals, Inc.$217
- Bausch & Lomb, A Division Of Bausch Health US, LLC$212
- plus $1K from 13 others
What the payments were for
- Food & beverage$3,582100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bausch & Lomb Americas Inc. | 22 | $669 |
| AbbVie(2 entities) | 27 | $579 |
| Sun Pharmaceutical Industries Inc. | 21 | $562 |
| Alcon | 12 | $254 |
| Tarsus Pharmaceuticals, Inc. | 11 | $217 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 10 | $212 |
| Aerie Pharmaceuticals, Inc. | 3 | $144 |
| Oyster Point Pharma, Inc. | 5 | $140 |
| Harrow Eye, LLC | 5 | $138 |
| Johnson & Johnson Vision Care, Inc. | 5 | $117 |
| Sight Sciences, Inc. | 3 | $113 |
| Novartis | 5 | $108 |
| Dompe US, Inc. | 3 | $78 |
| Shire North American Group Inc | 3 | $62 |
| Biotissue Holdings Inc. | 3 | $58 |
| Coopervision Inc. | 2 | $47 |
| Kala Pharmaceuticals, Inc. | 2 | $34 |
| Eyevance Pharmaceuticals LLC | 1 | $24 |
| Leadiant Biosciences, Inc. | 1 | $24 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,582 in reported general payments places this provider in the 80th percentile of 68 corneal and contact management providers in New York.
See all corneal and contact management providers in New York →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyzultaLatanoprostene Bunod | 96 | $56,035 |
| RestasisCyclosporine | 35 | $49,514 |
| LumiganBimatoprost | 78 | $47,404 |
| TyrvayaVarenicline Tartrate | 14 | $17,902 |
| CombiganBrimonidine Tartrate/Timolol | 27 | $12,737 |
| RocklatanNetarsudil Mesylat/Latanoprost | 12 | $11,685 |
| RhopressaNetarsudil Mesylate | 21 | $9,620 |
| Travoprost | 41 | $7,761 |
| Cyclosporine | 15 | $6,053 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 18 | $5,443 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 21 | $3,873 |
| Brinzolamide | 12 | $2,389 |
| Epinastine Hcl | 11 | $1,495 |
| Azelastine Hcl | 26 | $660 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 18 | $638 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan | $579 | $109,654140 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $669 | $56,03596 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $144 | $21,30533 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $140 | $17,90214 claims |
| AlconSimbrinza | $254 | $5,44318 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 68 corneal and contact management providers in New York.
Other corneal and contact management in New York
- Kevin RosinNew York$59K
- Kevork NiksarliNew York$27K
- Christina ChernyNew York$5K
- Nadine EisenbergNew York$4K
- Ralph GundelNew York$3K
- James SinowayNew York$3K
- Jennifer leNew York$3K
- Cynthia ZaraNew York$2K
- Frederic NevinsNew York$1K
- Melissa Lee KungNew York$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.